Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Zhong Yuan, Frank DeFalco, Lu Wang, Laura Hester, James Weaver, Joel N. Swerdel, Amy Freedman, Patrick Ryan, Martijn Schuemie, Rose Qiu, Jacqueline Yee, Gary Meininger, Jesse A. Berlin & Norman Rosenthal. (2020) Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion 36:7, pages 1117-1124.
Read now
Read now
Articles from other publishers (21)
Alekya Poloju, Priyanka Majety & Anna Groysman. (2023) Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin. AACE Clinical Case Reports.
Crossref
Crossref
Oscar Hou In Chou, Jiandong Zhou, Jonathan V Mui, Danish Iltaf Satti, Cheuk To Chung, Teddy Tai Loy Lee, Sharen Lee, Edward Christopher Dee, Kenrick Ng, Bernard Man Yung Cheung, Fengshi Jing & Gary Tse. (2023) Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis. Diabetes Epidemiology and Management 9, pages 100115.
Crossref
Crossref
Hibathulla Palapra, Subeesh K. Viswam, Vivekanandan Kalaiselvan & Krishna Undela. (2022) SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. International Journal of Clinical Pharmacy 44:6, pages 1425-1433.
Crossref
Crossref
Lin Zhang, Wei Mao, Xingxing Li, Xiaowen Wang, Jifang Liu, Sang Hu & Jing Hu. (2022) Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database. Frontiers in Pharmacology 13.
Crossref
Crossref
Ashlee D. Barrett, Mason A. Pitts, Elizabeth M. Myers & Jeremy L. Johnson. (2022) Probable Dapagliflozin-Associated Acute Pancreatitis. Diabetes Spectrum 35:2, pages 232-238.
Crossref
Crossref
Harry G. Preuss & Debasis Bagchi. 2022. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health
289
307
.
Ioana Frent, Camelia Bucsa, Daniel Leucuta, Andreea Farcas & Cristina Mogosan. (2021)
An investigation on the association between sodium glucose co‐transporter 2 inhibitors use and acute pancreatitis: A
VigiBase
study
. Pharmacoepidemiology and Drug Safety 30:10, pages 1428-1440.
Crossref
Crossref
Ekta Tirthani, Mina Said, Binita Neupane & Michael Quartuccio. (2021) An Unusual Case of the “Terrible Triad” in a Transgender Woman. Cureus.
Crossref
Crossref
Karolina N. Dziadkowiec, Peter M. Stawinski & Jose Proenza. (2021) Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors. ACG Case Reports Journal 8:1, pages e00530.
Crossref
Crossref
Swapnil P. Borse, Abu Sufiyan Chhipa, Vipin Sharma, Devendra Pratap Singh & Manish Nivsarkar. (2021) Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives. Medical Principles and Practice 30:2, pages 109-121.
Crossref
Crossref
Sunam M. Sujanani, Mohanad M. Elfishawi, Paria Zarghamravanbaksh, Francisco J. Cuevas Castillo & David M. Reich. (2020) Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Case Reports in Endocrinology 2020, pages 1-4.
Crossref
Crossref
Huilin Tang, Keming Yang, Xin Li, Yiqing Song & Jiali Han. (2020) Pancreatic safety of sodium‐glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Pharmacoepidemiology and Drug Safety 29:2, pages 161-172.
Crossref
Crossref
Laleh Razavi-Nematollahi & Faramarz Ismail-Beigi. (2019) Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. Current Diabetes Reports 19:11.
Crossref
Crossref
Shiqi Luo, George Binh Lenon, Harsharn Gill, Heidi Yuen, Angela Wei Hong Yang, Andrew Hung & Linh Toan Nguyen. (2019) Do the Natural Chemical Compounds Interact with the Same Targets of Current Pharmacotherapy for Weight Management?-A Review. Current Drug Targets 20:4, pages 399-411.
Crossref
Crossref
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson & Björn Pasternak. (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, pages k4365.
Crossref
Crossref
Kinner M. Patel, Erik Pikas & Tanya George. (2017) Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin. American Journal of Therapeutics 24:4, pages e496-e496.
Crossref
Crossref
Udaya M Kabadi. (2016) SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy. Journal of Diabetes, Metabolic Disorders & Control 3:5.
Crossref
Crossref
James J. Sterrett, Scott Bragg & Charles Wayne Weart. (2016) Type 2 Diabetes Medication Review. The American Journal of the Medical Sciences 351:4, pages 342-355.
Crossref
Crossref
Sara N. Trovinger, Sandra L. Hrometz, Sipan Keshishyan & Sidhartha D. Ray. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
453
462
.
. (2015) Canagliflozin. Reactions Weekly 1562:1, pages 53-53.
Crossref
Crossref
Udaya M. Kabadi. (2015) Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes. Journal of Diabetes Mellitus 05:04, pages 211-226.
Crossref
Crossref